Israel-based drug development company NeuroSense Therapeutics has partnered with QuantalX Neuroscience to improve early diagnosis and treatment of neurodegenerative diseases.

QuantalX is the developer of Delphi-MD brain imaging technology, a clinically objective neurodiagnostic medical device.

Delphi-MD technology supports real-time monitoring of brain functionality, resulting in improved patient care and reduced associated financial burden.

Under the collaboration, QuantalX will use its Delphi-MD device for early diagnosis and ongoing monitoring of trial participants in NeuroSense’s Phase 3 trial of PrimeC.

The trial will evaluate efficacy of Prime C in people living with amyotrophic lateral sclerosis (ALS), based on successful completion of its ALS Phase 2b trial.

QuantalX CEO and co-founder Iftach Dolev said: “We’re humbled and excited to join NeuroSense in its effort to advance therapies for neurodegenerative diseases, empower neurologists to provide better patient care through early detection and personalize disease management.”

Delphi-MD is said to provide definitive and quantitative, real-time brain function analysis through a first-in-class direct brain network visualisation technology.

The device magnetically stimulates the patients’ brain networks in a simple point of care affordable test, to enable early detection and differential diagnosis of brain abnormalities.

It is expected to provide multiple clinically objective and accurate measurements of brain function in NeuroSense’s upcoming AD Phase 2 clinical trial.

NeuroSense’s lead drug candidate, PrimeC, is a novel extended-release oral formulation composed of a unique fixed-dose combination of ciprofloxacin and celecoxib.

PrimeC targets several key mechanisms of ALS that contribute to motor neuron degeneration, inflammation, iron accumulation and impaired RNA regulation.

Under a collaboration with Massachusetts General Hospital on novel Neuron-Derived Exosomes (NDEs), the company is working to further determine the effect of PrimeC on biological changes in ALS-related pathologies.

NeuroSense CEO Alon Ben-Noon said: “We believe the use of cutting-edge innovations like Delphi-MD is the future of early detection and treatment of neurodegenerative diseases.

“We are enthusiastic to work with QuantalX, whose technology complements our extensive evaluation of our platform combination drug therapy via clinical measurements and a large panel of biomarkers.

“We envision a long-term collaboration beginning with our upcoming Phase 2 double-blind clinical study in Alzheimer’s disease, which we plan to commence in the first half of this year.”